Enovis Q2 revenue $395M (+11%), adjusted EPS $0.59 (+44%), full-year guidance updated

Enovis CORP

2022-Q2 EPS reported $1.69 revenue$770,574,000

Reported EPS from continuing ops $2.21; adjusted EPS $0.59 vs $0.41 YoY, includes ~$0.10 one-time tax benefit.
Organic growth 3% (5% per-day); adjusted EBITDA $56M, +11% YoY, with $2M currency pressure.
Completed acquisitions of Insight Medical Systems (ARVIS AR surgical guidance) and 360 Med Care (Australian distributor).
Updated FY2022 outlook: organic growth 6-9% reaffirmed; adjusted EBITDA $235-255M; adjusted EPS $2.15-$2.35.
Currency headwinds expected to impact full-year; Q2 tax planning benefit lifted adjusted EPS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.